

"Evaluation of Pharmacy Syringe Access Linked to HIV  
Testing for Injection Drug Users in New York City (Pharm-  
HIV)"

**Attachment 2**

**60-day Federal Register Notice**

**FEDERAL MARITIME COMMISSION****Notice of Change to Meeting**

*Agency Holding the Meeting:*

Federal Maritime Commission.

*Federal Register Citation of Previous Announcement:* 73 FR 67869.

*Previously Announced Time and Date of the Meeting:* 10 a.m. on November 20, 2008.

*Change:*

1. The addition of Item 2 to the Open Session of the Meeting: Item 2—FY 2009 Budget Status Report.

*For More Information Contact:*

Karen V. Gregory, Secretary, (202) 523-5725.

**Karen V. Gregory,**  
*Secretary.*

[FR Doc. E8-27598 Filed 11-17-08; 4:15 pm]

**BILLING CODE 6730-01-P**

**FEDERAL MARITIME COMMISSION****Ocean Transportation Intermediary License; Applicants**

Notice is hereby given that the following applicants have filed with the Federal Maritime Commission an application for license as a Non-Vessel Operating Common Carrier and Ocean Freight Forwarder—Ocean Transportation Intermediary pursuant to section 19 of the Shipping Act of 1984 as amended (46 U.S.C. Chapter 409 and 46 CFR 515).

Persons knowing of any reason why the following applicants should not receive a license are requested to contact the Office of Transportation Intermediaries, Federal Maritime Commission, Washington, DC 20573.

**Non-Vessel Operating Common Carrier and Ocean Freight Forwarder Transportation Intermediary Applicants**

InterChez Global Services, Inc., 3924 Clock Pointe Trail, Suite 101, Stow, OH 44224; Officer: Melissa F. Lines, Vice President, (Qualifying Individual).

Morrison Express Corporation (USA), 2000 Hughes Way, El Segundo, CA 90248; Officer: Douglas E. Haring, Vice President, (Qualifying Individual).

Dated: November 14, 2008.

**Karen V. Gregory,**  
*Secretary.*

[FR Doc. E8-27499 Filed 11-18-08; 8:45 am]

**BILLING CODE 6730-01-P**

**FEDERAL RESERVE SYSTEM****Formations of, Acquisitions by, and Mergers of Bank Holding Companies**

The companies listed in this notice have applied to the Board for approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C. 1841 *et seq.*) (BHC Act), Regulation Y (12 CFR Part 225), and all other applicable statutes and regulations to become a bank holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a bank or bank holding company and all of the banks and nonbanking companies owned by the bank holding company, including the companies listed below.

The applications listed below, as well as other related filings required by the Board, are available for immediate inspection at the Federal Reserve Bank indicated. The applications also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)). If the proposal also involves the acquisition of a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 4 of the BHC Act (12 U.S.C. 1843). Unless otherwise noted, nonbanking activities will be conducted throughout the United States. Additional information on all bank holding companies may be obtained from the National Information Center website at [www.ffiec.gov/nic/](http://www.ffiec.gov/nic/).

Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than December 12, 2008.

**A. Federal Reserve Bank of Atlanta** (Steve Foley, Vice President) 1000 Peachtree Street, N.E., Atlanta, Georgia 30309:

1. *Protective Life Corporation, Birmingham, Alabama*; to become a bank holding company by acquiring 100 percent of the voting shares of Bonifay Holding Company, Inc., and its subsidiary, The Bank of Bonifay, both of Bonifay, Florida.

**B. Federal Reserve Bank of Kansas City** (Todd Offerbacker, Assistant Vice President) 925 Grand Avenue, Kansas City, Missouri 64198-0001:

1. *Union State Banc Holding Company, Clay Center, Kansas*; to become a bank holding company by acquiring 100 percent of the voting shares of Union State Bank, Clay Center, Kansas.

**C. Federal Reserve Bank of San Francisco** (Tracy Basinger, Director, Regional and Community Bank Group) 101 Market Street, San Francisco, California 94105-1579:

1. *Marlin Business Services Corporation., Mount Laurel, New Jersey*; to become a bank holding company by acquiring 100 percent of the voting shares of Marlin Business Bank, Salt Lake City, Utah.

In connection with this application, Applicant also has applied to engage indirectly in leasing activities through Marlin Leasing Corporation, Mount Laurel, New Jersey, pursuant to 225.28(b)(3) of Regulation Y.

Board of Governors of the Federal Reserve System, November 14, 2008.

**Robert deV. Frierson,**

*Deputy Secretary of the Board.*

[FR Doc. E8-27470 Filed 11-18-08; 8:45 am]

**BILLING CODE 6210-01-S**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES****Centers for Disease Control and Prevention**

[60 Day-09-09AF]

**Proposed Data Collections Submitted for Public Comment and Recommendations**

In compliance with the requirement of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995 for opportunity for public comment on proposed data collection projects, the Centers for Disease Control and Prevention (CDC) will publish periodic summaries of proposed projects. To request more information on the proposed projects or to obtain a copy of the data collection plans and instruments, call 404-639-5960 or send comments to Maryam Daneshvar PhD, CDC Reports Clearance Officer, 1600 Clifton Road, MS-D74, Atlanta, GA 30333 or send an e-mail to [omb@cdc.gov](mailto:omb@cdc.gov).

*Comments are invited on:* (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information

technology. Written comments should be received within 60 days of this notice.

**Proposed Project**

“Evaluation of Pharmacy Syringe Access Linked to HIV Testing for Injection Drug Users in New York City (Pharm-HIV)”—New—National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP). Centers for Disease Control and Prevention (CDC).

*Background and Brief Description*

HIV continues to be one of the leading causes of illness and death in the US, especially among black and Hispanic communities. For injection drug users (IDU), who are at high risk of acquiring HIV infection, HIV testing may not be readily accessible. In 2001, the New York State Legislature established an Expanded Syringe Access Demonstration Program (ESAP) in New York City which made syringes available through participating

pharmacies for injection drug users. ESAP thus helped to reduce the burden of HIV by increasing access to sterile syringe sources. The ESAP allows for regular contact between pharmacists and their injection-drug-using syringe customers, thus paving the way for pharmacies to act as access points to health and social services among IDU customers. The expansion of pharmacy services to include referrals for injection-drug-using syringe customers is based on the successes of ESAP, which provides many services beyond syringe exchange.

This project involves two kinds of studies: testing service models at pharmacies and, interviewing individuals regarding the availability of syringes through pharmacies. For testing service models CDC will collaborate with the New York Academy of Medicine (NYAM) to implement this project for a period of three years.

The NYAM will identify 12 ESAP pharmacies in East Harlem, New York

City; ten of which will test a model that refers injection-drug-using syringe customers for HIV testing to local HIV testing sites. Two ESAP pharmacies will evaluate the feasibility of offering and performing HIV counseling and testing in the pharmacy for injection-drug-using syringe customers.

Two types of respondents will provide the individual-level data; forty-eight adult (age ≥18 yrs) pharmacy staff members will be surveyed to learn about pharmacy staff attitudes and behaviors regarding HIV testing and referral. The other respondent group will be 442 adult (age ≥18 yrs) injection-drug-using syringe customers who will complete a brief quantitative interview after HIV referral or HIV testing is offered to them. HIV-seropositive injection-drug-using syringe customers identified during HIV testing will be immediately linked to social and medical services. There is no cost to respondents other than their time.

ESTIMATE OF ANNUALIZED BURDEN TABLE

Types of data collection	Number of respondents	Number of responses per respondent	Average burden per response (in hours)	Total burden (in hours)
Pharmacy telephone screening and enrollment form .....	24	1	10/60	4
Pharmacy staff surveys—baseline, every six months x 3, and at end of study. ....	48	5	20/60	80
Pharmacy staff brief surveys—monthly except when 6 monthly surveys are completed. ....	12	19	10/60	38
Pharmacy daily syringe sales log .....	12	600	5/60	600
Injection-drug-using syringe customer surveys .....	442	1	30/60	221
Total .....	.....	.....	.....	943

Dated: November 7, 2008.

**Maryam I. Daneshvar,**

*Acting Reports Clearance Officer, Centers for Disease Control and Prevention.*

[FR Doc. E8-27448 Filed 11-18-08; 8:45 am]

BILLING CODE 4163-18-P

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Centers for Disease Control and Prevention**

**Subcommittee for Dose Reconstruction Reviews (SDRR), Advisory Board on Radiation and Worker Health (ABRWH), National Institute for Occupational Safety and Health (NIOSH)**

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC),

announces the following meeting for the aforementioned subcommittee:

*Time and Date:* 9:30 a.m.–5 p.m., December 8, 2008.

*Place:* Cincinnati Airport Marriott, 2395 Progress Drive, Hebron, Kentucky 41018. Telephone (859) 334-4611, Fax (859) 334-4619.

*Status:* Open to the public, but without a public comment period. To access by conference call dial the following information 1(866) 659-0537, Participant Pass Code 9933701.

*Background:* The Advisory Board was established under the Energy Employees Occupational Illness Compensation Program Act of 2000 to advise the President on a variety of policy and technical functions required to implement and effectively manage the new compensation program. Key functions of the Advisory Board include providing advice on the development of probability of causation guidelines that have been promulgated by the Department of Health and Human Services (HHS) as a final rule; advice on methods of dose reconstruction which have also been promulgated by HHS as a final rule; advice

on the scientific validity and quality of dose estimation and reconstruction efforts being performed for purposes of the compensation program; and advice on petitions to add classes of workers to the Special Exposure Cohort (SEC).

In December 2000, the President delegated responsibility for funding, staffing, and operating the Advisory Board to HHS, which subsequently delegated this authority to CDC. NIOSH implements this responsibility for CDC. The charter was issued on August 3, 2001, renewed at appropriate intervals, and will expire on August 3, 2009.

*Purpose:* The Advisory Board is charged with (a) Providing advice to the Secretary, HHS, on the development of guidelines under Executive Order 13179; (b) providing advice to the Secretary, HHS, on the scientific validity and quality of dose reconstruction efforts performed for this program; and (c) upon request by the Secretary, HHS, advising the Secretary on whether there is a class of employees at any Department of Energy facility who were exposed to radiation but for whom it is not feasible to estimate their radiation dose, and on whether there is reasonable likelihood